Placebo for ML-007C-MA bilayer tablet
ML-007C-MA-221
Phase 2 small_molecule active
Quick answer
Placebo for ML-007C-MA bilayer tablet for Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis is a Phase 2 program (small_molecule) at MapLight Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MapLight Therapeutics
- Indication
- Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active